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Abstract
Whereas the association between intestinal microorganisms and health has been widely accepted in the area of infectious disease, recent
advances have now implied a role for the intestinal microbiota in human energy balance. In fact, numerous studies support an intricate
relationship between the intestinal microbiota and obesity, as well as subsequent insulin resistance and non-alcoholic fatty liver disease.
Intestinal microorganisms also seem to be involved in haemostatic tone and atherogenesis. However, as most of the ﬁndings stem from
observational data, intervention studies in humans using interventions selectively aimed at altering the composition and activity of the
intestinal microbiota are crucial to prove causality. If substantiated, this could open the arena for modulation of the intestinal microbiota as a
future target in obesity-associated disease, both as a diagnostic test for personalized algorithms and for selective therapeutic strategies.
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Introduction
Obesity is an increasingly important public health issue, as it is
expected that, by 2030, one-third of the population of the
western world will be obese [1]. The term ‘metabolic
syndrome’ is widely used as a clinical deﬁnition of overweight
individuals at increased risk of a large series of comorbidities,
such as insulin resistance, cardiovascular disease (CVD),
venous thromboembolic events, and non-alcoholic fatty liver
disease (NAFLD) [2] (Fig. 1) . Apart from many other genetic
risk factors that play a role in the development of obesity [3],
metabolic syndrome is increasingly thought to be a chronic
inﬂammatory disease driven by chronic intestinal bacterial
translocation resulting in endotoxaemia [4,5]. Endotoxaemia is
characterized by Gram-negative bacterial capsule fragments in
the plasma, and is linearly associated with the concentration of
lipopolysaccharide-binding protein in plasma. In this regard,
plasma lipopolysaccharide-binding protein was found to be a
marker of chronic inﬂammation associated with the develop-
ment of obesity and insulin resistance in both mice and humans
[6,7]. Moreover, there is increasing evidence that the intestinal
microbiota might contribute to host metabolism and obesity
[8], a process that is thought to stem from impaired gut barrier
function in obese subjects [9].
The average human bowel is home to trillions of microor-
ganisms, mainly bacteria, but also viruses and a low number of
fungi, which outnumber the cells of their human host by a
factor of ten to one [10]. In fact, their genes even outnumber
the human genes by >100-fold. Microbial colonization starts
soon after birth and, although the initial composition of the
microbiota varies, it becomes relatively stable after the age of
3–4 years, and remains so into advanced age [10]. The
intestinal microbiota serves as an ‘exteriorized’ organ, com-
plementing and interacting with human metabolism, and so
giving rise to novel therapeutic targets. In this respect, the
composition of the intestinal microbiota and its collective
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genome (also known as the microbiome) is considered to be
an important factor in various diseases, ranging from gastro-
intestinal tract disease to obesity [11]. Bacterial numbers and
composition vary considerably along the human gastrointesti-
nal tract. In the oral cavity, there are approximately 1012
bacteria; the numbers in the stomach and small intestine are
signiﬁcantly lower, owing to the rapid transit times and the
secretion of gastric acid, and bile and pancreatic juice. Bacterial
numbers range from 100 to 104 per gram in the stomach,
whereas the proximal small intestine and the ileum harbour
105–107 and up to 107–108 bacteria per gram of intestinal
content, respectively. The highest number of bacterial cells is
found in the large intestine, with approximately 10¹¹ per gram
of intestinal content [12]. Quantitatively, the most important
phyla of the intestinal microbiota include the Firmicutes,
Bacteroidetes, Actinobacteria, Proteobacteria, and Verrucomicrobia,
the representatives of which are often regarded as strict
anaerobes (except for the Proteobacteria, which can be
facultative anaerobes) [12]. Older literature has suggested
that germ-free animals are less susceptible to obesity [13] and
atherosclerotic plaque [14] and thrombus formation [15],
suggesting that the intestinal microbiota may play a role in
these cardiometabolic diseases [16]. Until recently, knowledge
of the intestinal microbiota was limited, mainly because of the
lack of methods for growing and identifying their representa-
tives. The introduction of culture-independent approaches
based on analysis of 16S rRNA and its corresponding genes has
profoundly changed the landscape; these topics have already
been covered in recent reviews [11,17,18]. Nevertheless,
owing to the use of different analysis platforms, reproducibility
issues, and other biases, including concomitant medication use
in selected subjects, inconsistent results have been generated
by these observational studies, and this calls for caution in their
interpretation [17]. In the present article, we will discuss the
potential inﬂuence of the intestinal microbiota on the devel-
opment of obesity-associated parameters such as NAFLD and
hypercoagulability. The underlying pathophysiological pro-
cesses, including microbiota-associated chronic low-grade
inﬂammation, and potential therapeutic targets are also
described.
Gut microbiota, inﬂammation and lipid metabolism
It is widely acknowledged that obesity and subsequent insulin
resistance are closely related to the presence of adipose tissue
inﬂammation. As adipose tissue is important for the produc-
tion of various inﬂammation cytokines [19], there is ample
FIG. 1. Potential associations between the
intestinal microbiota and obesity-related com-
orbidities, comprising insulin resistance, cardio-
vascular disease, venous thromboembolic
events and non-alcoholic fatty liver disease
(NAFLD). GMB, Gut microbiota; LPS, lipopoly-
saccharide; PAI-1, plasminogen activator inhib-
itor-1; SCFA, short-chain fatty acid; TMAO,
trimethylamine-N-oxide.
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evidence that visceral adipose tissue and, to a lesser extent,
subcutaneous adipose tissue drive the development of insulin
resistance [20]. More recently, the numbers of visceral adipose
tissue macrophages and crown-like structures (or accumulated
CD68-positive macrophages) were found to correlate with
inﬂammatory gene expression [21], suggesting a role for the
innate immune system in this process [22]. Likewise, changes
in the intestinal microbiota could induce a chronic inﬂamma-
tory tone in obesity [23], which drives activation of pattern
recognition receptors, such as toll-like receptors (TLRs), by
bacterial endotoxins (e.g. lipopolysaccharide (LPS)) that bind
to TLRs or other pattern recognition receptors, thus activating
the innate immune system [24]. It should, however, be noted
that, in addition to LPS, the intestinal microbiota is a source of
many other proinﬂammatory molecules, such as peptidogly-
cans [25] and ﬂagellins [26], which are also able to activate
inﬂammatory pathways [27]. Nevertheless, several lines of
evidence suggest a causal relationship between endotoxaemia
and obesity, as LPS infusion in mice [24] resulted in fasting
hyperglycaemia/dyslipidaemia and hyperinsulinaemia, hepatic
insulin resistance, obesity, hepatic steatosis, and macrophage
inﬁltration of visceral adipose tissue. Interestingly, these effects
were also found when mice were put on a high-fat diet for
4 weeks. To further demonstrate the relationship between
LPS and these effects, CD14-knockout mice (CD14 forms a
complex with TLR4 that is vital to the innate immune system
for binding of LPS) were given the same LPS infusion, and these
mice proved to be resistant to the development of low-grade
inﬂammation and dyslipidaemia. With hindsight, this may not
have come as a surprise, as previous studies suggested an
important role for plasma lipoproteins in the clearance of
endotoxins, including very low-density lipoprotein particles
[28] and high-density lipoprotein cholesterol [29,30], whereas
postprandial chylomicronaemia was associated with an
increased plasma endotoxin load [31]. On the other hand,
the intestinal microbiota composition itself can also affect lipid
metabolism [27], as bacterially produced short-chain fatty
acids (SCFAs) affect lipolysis [13,32]. Together, these obser-
vations suggest bi-directional cross-talk between the intestinal
microbiota, chronic inﬂammatory tone, and SCFA metabolism.
Gut microbiota, obesity, and NAFLD
NAFLD is closely related to obesity, metabolic syndrome, and
insulin resistance [33], and its worldwide prevalence is rapidly
increasing [34]. The most extreme form of NAFLD is non-
alcoholic steatohepatitis (NASH), a chronic liver disease that
has the potential to progress to liver cirrhosis, liver failure, and
hepatocellular carcinoma [35]. An increasing amount of data
showing a causal link between the small-intestine microbiota
and NAFLD in animals has emerged [4,36], all hinting at
separate pathophysiological pathways. First, the postprandial
increase in the plasma endotoxin concentration in the portal
vein may exceed the clearance capacity of the hepatic Kupffer
cells in individuals with obesity [31], resulting in systemic
endotoxaemia and low-grade chronic inﬂammation [37].
Indeed, recent data indicate that exogenous stimuli, such as
dietary choline, can directly drive the intestinal microbial
composition and subsequent intestinal permeability and NA-
FLD/NASH [36,38,39] . This metabolic state is mostly mediated
by bacterial endotoxins such as LPS [40] derived from intestinal
bacteria (e.g. proteobacteria) that are found in relatively large
numbers in the intestines of obese subjects [9]. As previously
mentioned, obese individuals are thought to have increased
intestinal permeability, partly because of TLR4 induction [41]
and altered tight junction proteins [42], potentially resulting in
an increased endotoxin load in the portal vein, with ensuing
overload of the hepatic Kupffer cells. This results in a so-called
‘ﬁrst hit’. In this ‘ﬁrst hit’, liver injury occurs through cytokine
release (tumour necrosis factor-a) and ﬁbrogenesis [43].
However, constant activation of TLRs in Kuppfer cells leads
to a decrease in TLR tolerance (second hit), inducing chronic
liver disease [44]. Indeed, chronic exposure to low-dose LPS in
mice has been shown to induce NASH, whereas TLR4
knockout mice (lacking the receptor that binds LPS and
consequently activates the innate immune system) seem to be
protected, suggesting a potential causal link between obesity,
the intestinal microbiota, and the development of NASH [45].
Gut microbiota, obesity, and coagulation
Obesity and metabolic syndrome are intrinsically linked and
are associated with NASH and hypercoagulability [2,33,46]. In
this respect, increased thrombin generation dependent on
vitamin K-dependent clotting factors (II, VII, IX, and X) has
been demonstrated in obese humans [47]. In this respect, the
liver contains the largest (90%) vitamin K pool, which is
derived from two natural vitamins. These are phylloquinone
(also known as vitamin K1), which comes from the diet (in
particular, vegetables), and menaquinone (also known as
vitamin K2), which is produced by intestinal bacteria [48]. It
was recognized long ago that the amount of endogenous
vitamin K synthesis by the microbiota (e.g. the Firmicutes) in
the distal intestine greatly exceeds the required daily dose
required to prevent haemostatic disorders [49]. Indeed,
hepatic vitamin K1 stores are depleted in healthy subjects
without affecting haemostatic tone within days after dietary
vitamin K restriction, as levels of intestinal microbiota-derived
vitamin K2 remain stable for several weeks [50]. Other
indirect evidence for a role of the intestinal microbiota in
haemostatic activity stems from intervention studies with
vitamin K antagonists in healthy subjects. Administration of
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vitamin K2 alone directly increases factor VII plasma levels in
these subjects, resulting in a normalized haemostatic tone and
suggesting a role for bacterially synthesized vitamin K2 in
overall human haemostasis [51]. With respect to a causal role
of the intestinal microbiota in hypercoagulability, direct
evidence is limited. Reinhardt et al. [52] showed that intestinal
tissue factor levels are regulated by the intestinal microbiota.
More indirect data suggest a regulatory role for the intestinal
microbiota in the inhibition of ﬁbrinolysis through plasminogen
activator inhibitor-1 via SCFAs produced by the gut microbiota
[53]. This is of particular interest, as obese human subjects are
reported to have reduced intestinal SCFA production [8].
Moreover, a strong correlation between obesity, NAFLD and
hypercoagulability has been described [2,33,46,54]. For example,
obesity is associated with increased plasma concentrations of
procoagulant factors (tissue factor, factor VII, and ﬁbrinogen)
and decreased ﬁbrinolysis [2] (increased plasminogen activator
inhibitor-1 activity and decreased tissue plasminogen activity). In
line with this, the levels of plasma coagulation factors VIII, IX, XI
and XII are increased in patients with NAFLD, and are positively
related to hepatic fat content [55]. This hypercoagulability
directly leads to an increased risk of venous thromboembolic
events [56]. Nevertheless, it is still unclear which small-intestine
or large-intestine bacterial species are involved in the aetiology
of this hypercoaguable state, and to what extent targeted
intervention can normalize the intestinal microbiota composi-
tion in obese humans with NAFLD.
Gut microbiota, obesity, and atherosclerosis
As current therapeutic regimens prevent only 25% of all
cardiovascular events, atherosclerosis still remains one of the
major health problems throughout the western world, in
particular in subjects with moderate to severe obesity [57]. It
has beenwell established that obesity, NAFLD and dyslipidaemia
are important risk factors for the development of atheroscle-
rosis and subsequent CVD [58]. In addition, chronic low-grade
inﬂammation induced by intestinal microbiota-derived endot-
oxaemia was recently found to be a risk factor for obesity,
NAFLD, and insulin resistance [59]. In the Bruneck study, plasma
endotoxin levels above the 90th percentile were associatedwith
a three-fold increase in cardiovascular event risk [60], and
animal experiments clearly demonstrated that endotoxin injec-
tion accelerates cholesterol-induced atherosclerosis [61]. In
this section, we will therefore focus on the role of the intestinal
microbiota in the induction of an inﬂammatory state ultimately
contributing to accelerated atherogenesis.
As previously mentioned, another driving factor for chronic
low-grade endotoxaemia might be the co-transport of intes-
tinal bacteria via intestinal uptake of dietary lipoproteins
(chylomicrons) [62]. Recent data have shown that dietary fat
promotes intestinal absorption of LPS from the gut microbiota
in apical intestinal epithelial cells, which may subsequently
contribute to various inﬂammatory disorders [63]. In this
respect, several studies have reported on the association
between the intestinal microbiota and obesity and its sequelae,
dyslipidaemia and insulin resistance [64], as germ-free mice on a
high-fat diet were characterized by lower plasma cholesterol
concentrations and less hepatic triglyceride, phosphatidylcho-
line and tricarboxylic acid accumulation than conventionally
raised mice [65]. Interestingly, these hepatic lipids have also
been implicated in the development of human NAFLD [66].
Dietary phosphatidylcholines, for example, were directly
related to the intestinal microbiota and subsequent CVD, as
these lipids are catabolized by the gut microbiota into
trimethylamine, which is subsequently converted to trimethyl-
amine-N-oxide (TMAO) in the liver [16]. In this landmark study,
it was shown that plasma levels of choline and TMAO are
directly correlated with the percentage of foam cells in
atherosclerotic lesions of conventionally raised mice, as well
as the degree of dyslipidaemia and cardiovascular events in
humans. The causal relationship between TMAO, the intestinal
microbiota and CVD was underscored by the fact that broad-
spectrum oral antibiotic treatment signiﬁcantly reduced TMAO
plasma levels and atherosclerotic lesion formation in mice. In
line with this observation, obese patients with NAFLD are
characterized by dyslipidaemia, increased oxidative stress, and
an increased atherosclerotic burden [67–69]. Thus, these data
lend further support for a relationship between the intestinal
microbiota, NAFLD and chronic inﬂammation driving dyslip-
idaemia and cardiovascular inﬂammation.
Gut microbiota, NAFLD and atherothrombosis in obesity:
novel therapeutic options
As the number of studies on the intestinal microbiota is
increasing, the number of associations with this biological
factor are increasing [11]. To date, animal models have been
mainly used to study the associations with the intestinal
microbiota. Although they are useful in providing mechanistic
insights, these results cannot be directly extrapolated to
humans. Nevertheless, these ﬁndings may hint at potentially
useful therapeutic interventions, which obviously should be
validated in the human clinical setting.
First, the intestinal production of vitamin K2 can be
disrupted by short-term oral antibiotic use. It was shown in
post-mortem liver samples that there was a ﬁve-fold reduction
in the endogenous vitamin K2 content in individuals who had
received broad-spectrum antimicrobials prior to death [70].
Moreover, similar effects of antibiotics on haemostatic tone
have been reported in humans [71], with an increased
incidence of hypothrombinaemia being related to the eradication
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of intestinal vitamin K2-producing bacteria [72]. Although
more research is needed, one could hypothesize that the
administration of speciﬁc microbial strains as probiotics may
affect the biosynthesis of hepatic clotting factors, and that they
could serve as natural anticoagulants in obese subjects.
Second, bacterial DNA from Porphyromonas gingivalis has
been isolated in human carotid plaque material, reﬂecting the
presence of naturally occurring microorganisms of the oral
cavity [73] and gut [74] in atheroma. Older data had already
suggested a strong relationship between Chlamydia pneumoniae
infection, acute coronary syndrome, and atherosclerosis [75].
Unfortunately, all randomized controlled intervention trials
[76] aimed at reducing cardiovascular events by targeted
antibiotic treatment have proven unsuccessful in patients at
increased cardiovascular risk. Statins, however, are known to
lower CVD risk even in apparently healthy men and women
with chronically increased inﬂammatory tone [77]. Interest-
ingly, statins might reduce the number of bacterial infections
and endotoxaemia-induced inﬂammation by blocking TLR
activation [78,79]. As a recent study suggested a direct effect
of the intestinal microbiota on statin metabolism [80], it is
tempting to speculate about potential beneﬁcial effects of
statin therapy on the small-intestine microbiota composition,
reduced bacterial translocation, and subsequent CVD. Like-
wise, 6 months of treatment with the peroxisome prolifera-
tor-activated receptor-c agonist pioglitazone led to metabolic
and histological improvement of NASH in obese subjects [81].
As in vitro experiments demonstrated that peroxisome prolif-
erator-activated receptor-c activation can reduce the pro-
inﬂammatory capacity of intestinal bacteria [82], it is tempting
to speculate that part of the above-mentioned clinical
improvement could be induced via the altered small-intestine
microbiota composition induced by glitazones.
Finally, a recent study suggests that the intestinal microbiota
metabolites can positively affect the reverse cholesterol
transport pathway by affecting ABCA1/ABCG1-cholesterol-
mediated efﬂux [83]. Although data on the role of intestinal
cholesterol metabolism and microbiota are not available for
humans, a direct correlation between actinobacteria and low-
density lipoprotein cholesterol has been reported, and a set of
potentially pathogenic proteobacteria showed a negative
correlation with phosphatidylcholines [84]. Moreover, we
have recently reported on our experience with the effect of
healthy-donor gut microbiota infusions (or faecal microbiota
transplantations) on insulin resistance in obese subjects with
the metabolic syndrome [8]. We are currently testing the
effects of lean-donor faecal microbiota transplantation on
intestinal cholesterol ﬂuxes. Using this human set-up, we hope
to identify speciﬁc strains of intestinal bacteria associated with
beneﬁcial systemic effects on cardiometabolism, which could
subsequently lead to the development of novel, microorgan-
ism-based intervention strategies.
In conclusion, an accumulating body of evidence relates
imbalances in the composition of the intestinal microbiota to
obesity and associated cardiometabolic disorders. The exact
mechanisms by which the microbiota alters cardiometabolic
homeostasis are being investigated in numerous research
programmes. In the midst of this active area of research,
there is an increasing need to closely apply Koch’s’ postulates
to dissect causality from association. Thus, experimental
ﬁndings on correlations between obesity and microbial
communities should be corroborated by therapeutic studies
in humans for their potential to prevent human disease and
promote health.
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